Dec 30, 2010: ‘NF2 News’ winter 2010 newsletter by the NFA, in the UK. – Interesting opening article on the NFA’s new 5 year plan. Also, a very interesting article on Avastin™ for NF2, page 7. Dec 1, 2010: CTF announces a Phase 2 of the DDI ‘NF Preclinical Consortium’ (NFPC). Funding (at $1/4M each… Continue Reading →
News & Announcements
The 6th annual Halloween Bash to benefit Children‘s Hospital Oakland and to find a cure for Neurofibromatosis type 2 took place on Friday, October 22nd in Walnut Creek, California. Roland and Nicole Thoms have been throwing this Halloween party since 2003, a year after their daughter,Camille (then 7 years old) was taken to the hospital… Continue Reading →
Advocure NF2 Inc wrote to and asked Dr. Naba Bora of the Congressional Directed Research Programs (CDMRP NFRP) for clarification on CDMRP’s grant funding mechanism, as well as to explain its present NF Consortium centers lack of ̳NF2 expertise.
On August 23, 2010, Advocure NF2 was invited to participate in a conference call with both Bruce R. Korf, MD, PhD (Principal Investigator of the NF Consortium) and Dr. Roger Packer (Chair of the Consortium), in order to clarify the NF Consortium’s timeline on NF2’s inclusion for trials.
Update 2016 – Due to the unfortunate passing of Dr Guha, this trial has been closed. A new NF2 Phase 2 clinical trial has been announced using Nilotinib, the second generation of Gleevec (which has been used for decades in a variety of other human tumors). This trial will be through the University Health Network… Continue Reading →